The XXII NIBIT Meeting, scheduled to take placefrom October 23-25, 2025 IN Livorno. The XXII NIBIT Meeting will continue to be at the forefront of cancer immunology and immunotherapy,with a strong focus on clinical advancements across a variety of cancers.<\/p>\n
As the field of Tumor Biotherapy continues to evolve, next year\u2019s sessions will highlight cutting-edgedevelopments in human cancers such as non-small cell lung cancer (NSCLC), melanoma, hepatocellular carcinoma, gastrointestinal cancers, and breast cancer. These will include both established and emerging immunotherapy approaches.<\/p>\n
Additionally, the meeting will delve into transformative technologies shaping the future of oncology,including AI-driven diagnostics, single-cell analysis, and spatial mapping of tumor microenvironments. These innovations aim to facilitate the development of personalized treatment strategies.<\/p>\n
Now at its twenty-second edition, the annual NIBIT Meeting is among the most important scientific events in the field of immuno-oncology in Italy and Europe.
The emphasis on translational medicine, the interaction between clinicians and researchers, the attention to the most innovative research lines, the presence of international researchers, together with a rigorous independence from the industry, are the characteristics that make the NIBIT Meeting an essential event for all professionals (doctors, scientists, industry representatives, research nurses, data managers) involved in research and medicine in oncological immunotherapy.<\/p>\n
In addition to the scheduled presentations and abstracts received, we will have the honor of attending the “Pezcoller Lecture” delivered by Marco Colonna, Professor of Pathology & Immunology at Washington University School of Medicine in St. Louis, MO, USA and member of the National Academy of Science.<\/p>\n
Dr. Colonna\u2019s research focuses on immunoreceptors. In this field his accomplishments encompass identification and characterization of the Killer cell Ig-like receptors and HLA-C polymorphisms as their inhibitory ligands, as well as the discovery of the LILR and TREM inhibitory and activating receptor families. Through analysis of the cellular distribution of these receptors, he identified plasmacytoid dendritic cells as source of IFN-a\/b in anti-viral responses and innate lymphoid cells that produce IL-22 in mucosae. His current areas of research include: 1) Innate lymphoid cells in mucosal immunity. 2) Plasmacytoid dendritic cells in host defense and autoimmunity.3) TREM2 and innate immunoreceptors in Alzheimer\u2019s disease and cancer.<\/p>\n
\t All participants are encouraged to submit an abstract in English. The abstracts will be reviewed by the Scientific Committee and selected for oral or poster presentation. When submitting the abstract, presenting authors must select one of the following topics:<\/p>\n \u00a0<\/strong>The abstract should respect the following guidelines:<\/p>\n Abstract Selection Process<\/u><\/strong><\/p>\n The Scientific Committee will make the selection of abstracts for the oral or poster presentation. Please note that submitting an abstract does not constitute registration for the meeting.<\/p>\n \t NIBIT will offer a limited number of Travel Grants.<\/p>\n The Grant will cover the travel expenses up to the amount of \u20ac 500. The reimbursement will be provided by bank transfer after the end of the meeting, upon receipt of flight and\/or ground transportation tickets\/invoices.<\/p>\n To be eligible you have to:<\/p>\n To apply, please upload a CV or a bio sketch, including your publications, when submitting the abstract. Applications are subject to approval by the Scientific Committee<\/p>\n \t
\n\t\tDownload scientific program (PDF)
\n\t\t\t<\/a><\/p>\nCall for abstract<\/h3>\n
\n
\n
<\/ul>\n
\n\t\tClick here to submit your abstract
\n\t\t\t<\/a><\/p>\nTravel grants<\/h3>\n
\n
Registration<\/h3>\n
\n\t\tOnline registration form
\n\t\t\t<\/a><\/p>\n\n\n
\n REGISTRATION TYPE\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/strong>Closing at 23.59 on July 23<\/em><\/td>\n<\/tr>\n \n <\/td>\n Advance registration<\/td>\n Regular registration<\/td>\n<\/tr>\n \n NIBIT Member \u2013 over35<\/td>\n \u20ac 220,00 VAT incl.<\/td>\n \u20ac 250,00 VAT incl.<\/td>\n<\/tr>\n \n NIBIT Member \u2013 under 35<\/td>\n \u20ac 120,00 VAT incl.<\/td>\n \u20ac 150,00 VAT incl.<\/td>\n<\/tr>\n \n NIBIT Member \u2013 Post doc<\/td>\n \u20ac 120,00 VAT incl.<\/td>\n \u20ac 150,00 VAT incl.<\/td>\n<\/tr>\n \n NIBIT Member -PhDStudent<\/td>\n \u20ac 120,00 VAT incl.<\/td>\n \u20ac 150,00 VAT incl.<\/td>\n<\/tr>\n \n NIBIT MemberResident<\/td>\n \u20ac 120,00 VAT incl.<\/td>\n \u20ac 150,00 VAT incl.<\/td>\n<\/tr>\n \n UndergraduateStudent<\/td>\n free of charge<\/td>\n free of charge<\/td>\n<\/tr>\n \n Non-member (all categories)<\/td>\n \u20ac 320,00 VAT incl.<\/td>\n \u20ac 350,00 VAT incl.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n